What are you looking for ?
Advertise with us
RAIDON

Altai Capital Management Not Happy With Emulex’s Acquisition of Endace

In letter to CEO Jim McCluney

Altai Capital Management, L.P. sent a letter to Jim McCluney, CEO of Emulex Corporation, on May 7, 2013. Here is a large abstract.

Dear Mr. McCluney:

In our letter to you dated February 20, 2013, we expressed concern that the board of Emulex Corporation did not have appropriate shareholder representation.

On April 1, 2013, Emulex announced that it had appointed Gene Frantz and Greg Clark to its board of directors. We believe that Emulex working in collaboration with Elliott Management, the company’s largest shareholder, to add Mr. Frantz and Mr. Clark to its board is a step in the right direction.

In our prior letter, we also expressed disappointment that Emulex had chosen to pursue an acquisition of Endace Limited, which the company closed on April 1, 2013. Since announcing its intent to acquire Endace on December 5, 2012, Emulex’s share price has materially underperformed the market as well as its closest competitor, QLogic Corporation.

We believe that much of Emulex’s share price underperformance since December 2012, especially relative to QLogic, can be directly attributed to the company’s decision to proceed with the Endace acquisition. Since announcing its intent to acquire Endace, Emulex’s cash per share declined by approximately $1.08. Concurrently, Emulex’s share price declined by the same amount, implying that the equity market values Emulex’s cash far more than this acquisition.

Although we believe that the Endace business has value, we sympathize with public market investors. Emulex management has provided very little commentary regarding its internal projections for Endace. On Emulex’s last earnings call, CFO Michael Rockenbach stated that Endace "will comprise as much as 8%" of fourth quarter revenue. Even if Emulex were to double Endace’s revenue and dramatically improve its margins, it would still take many years before Emulex recouped its $130 million investment.    

Currently, Emulex trades at low valuation multiples relative to many of its peers. As we stated in our last letter, we believe this discount is in part due to investors’ dim view of Emulex’s future growth prospects, an opinion with which we strongly disagree.

Unfortunately, we must also conclude that Emulex’s valuation discount is somewhat deserved owing to valid investor concerns regarding management’s ability to allocate capital, accurately forecast its business, and make sound decisions on behalf of shareholders. It is hard for us to ignore that on July 9, 2009, Emulex rejected Broadcom Corporation’s $11 per share bid for the company. If your board had accepted that offer, shareholders clearly would be much better off than they are today.

In its July 2009 press release, Emulex stated that Broadcom’s offer "significantly undervalue[d] Emulex’s long-term prospects, [was] inadequate, and [was] not in the best interests of Emulex and its stockholders." In addition, you stated in the release that 2009 design wins further validated projections of "$600 million in revenue and $1.45 in non-GAAP earnings per share in fiscal year 2012, and reinforce[d] additional upside opportunities available to the company." Sadly, in hindsight this projection has proven to be overly optimistic.

Given your sizable forecast miss in the midst of a decision that had enormous economic consequences for your shareholders, we believe it will take many years for management to regain credibility in the public markets. Still, we are confident that Emulex continues to possess valuable assets and has a bright future. We contend that the best course of action is for Emulex to initiate a sale process, and we therefore request that the current board engage financial advisors immediately to undertake this task in earnest. We believe that a sophisticated buyer with the opportunity to properly diligence the company could pay a healthy premium to today’s share price and still earn an excellent return.

Absent a sale of the entire business, Altai Capital would only be satisfied as a long-term shareholder in the event of wholesale change at the board level. The board members who rejected Broadcom’s $11 per share bid for Emulex and/or oversaw the Endace transaction have done shareholders a significant disservice. Therefore, we intend to consider all of our options with regard to this year’s annual meeting in order to restore investor confidence and ultimately improve outcomes for shareholders.

Sincerely,

Rishi Bajaj, chief investment officer
Altai Capital Management

Articles_bottom
ExaGrid
AIC
ATTOtarget="_blank"
OPEN-E